Loading clinical trials...
Loading clinical trials...
The Intestinal Microbiota as a Therapeutic Target in Hospitalized Patients With COVID-19 Infection
A prospective case-control pilot study to evaluate the possible effect of a probiotic mixture in the improvement of symptoms, the reduction in the number of days of hospitalization and the increase in the percentage of patients with negative PCR after infection with the coronavirus SARS-CoV-2.
In this study, the investigators hypothesize a positive effect of probiotic on the gut microbiome that could led to produce a less severe clinical evolution of the disease.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Hospital Universitario del Vinalopó
Elche, Alicante, Spain
Hospital Universitario de Torrevieja
Torrevieja, Alicante, Spain
Start Date
May 4, 2020
Primary Completion Date
March 21, 2021
Completion Date
April 30, 2021
Last Updated
April 29, 2022
41
ACTUAL participants
Probiotic
DIETARY_SUPPLEMENT
Lead Sponsor
Bioithas SL
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06631287